Accredo Health Group has been chosen as a specialty pharmacy provider for the new replacement enzyme idursulfase (Elaprase, Shire Genetic Therapies), used to treat Hunter syndrome, a rare, but life-threatening lysosomal storage disorder. Accredo will provide pharmacy management and prescription fulfillment services through its network of 39 pharmacies. Caremark Specialty Pharmacy will be the other provider to distribute the therapy.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.